Eli Lilly Warns of Safety Risks with Compounded Tirzepatide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Source: seekingalpha
- Safety Risk Warning: Eli Lilly has issued a warning regarding compounded tirzepatide mixed with vitamin B12, revealing significant levels of impurities that could lead to toxicity and immune reactions, thus alerting patients to the potential dangers of using such products.
- FDA Recall Request: The company urged the FDA to recall all compounded tirzepatide products mixed with untested additives, emphasizing its commitment to consumer safety and the need to mitigate unknown risks associated with these medications.
- Competitive Market Pressure: Eli Lilly faces pressure from cheaper copycat versions of its drugs that bypass strict regulatory approval processes, despite the FDA declaring that the supply shortage has been resolved, meaning compounded medications are no longer permitted.
- Industry Dynamics Shift: Hims & Hers has entered into an agreement with Novo Nordisk to discontinue its compounded GLP-1 products in favor of Novo's weight-loss drugs, indicating a growing market preference for compliant products over unregulated alternatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1107.080
Low
950.00
Averages
1192
High
1500
Current: 1107.080
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lilly Launches MedicareGLP-1Bridge Program for Obesity Treatments
- New Medicare Pathway: Lilly announced the MedicareGLP-1Bridge program effective July 1, 2026, allowing eligible Medicare Part D patients to access Foundayo and Zepbound for $50 per month, marking a significant increase in treatment options for obesity.
- Expanded Coverage: This program will provide broad GLP-1 drug coverage for Medicare Part D patients for the first time, potentially benefiting around 20 million eligible patients and promoting obesity treatment accessibility, particularly among adults aged 65 and older.
- Significant Clinical Outcomes: Clinical trials demonstrated that Foundayo and Zepbound resulted in meaningful weight loss in patients aged 65 and older, with Foundayo achieving an average weight loss of 13% in non-diabetic patients at the highest dose, while Zepbound showed over 56.7% of patients losing at least 20% of their body weight over 72 weeks, highlighting its effectiveness in older populations.
- Long-term Strategic Implications: This initiative not only enhances the accessibility of Lilly's obesity medications but also solidifies its leadership in chronic disease treatment, reflecting the company's commitment to recognizing obesity as a chronic condition, which is expected to drive future sales growth and market share expansion.
See More
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals
- Acquisition Completed: Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, aimed at expanding its neuroscience portfolio, particularly in sleep medicine.
- Drug Development Progress: Centessa's lead drug candidate, Cleminorexton, is undergoing Phase 2a clinical studies targeting narcolepsy and other sleep disorders, indicating significant market potential and therapeutic prospects.
- Financial Structure: Under the agreement, Lilly acquired Centessa for $38 per share in cash, along with a non-transferable contingent value right of up to $9 per share, potentially adding $1.5 billion in value upon achieving specific regulatory milestones.
- Market Performance: Lilly's stock has traded between $623.78 and $1,182.73 over the past year, currently priced at $1,111.53, reflecting a 0.51% increase from the previous trading day, indicating positive market sentiment regarding the acquisition.
See More
Three Healthcare Stocks Positioned to Thrive with AI
- Eli Lilly's AI Innovation: Eli Lilly's partnership with Nvidia to build the industry's most powerful supercomputer is expected to shorten the drug discovery phase by 1-2 years, potentially saving around $2.8 billion in R&D costs, enhancing profit margins, and lowering drug prices for patients.
- Novo Nordisk's AI Application: Novo Nordisk's collaboration with OpenAI aims to improve drug development efficiency, particularly in obesity and diabetes treatments; despite recent sales growth challenges, its robust pipeline and the promising UBT251 drug could facilitate a future recovery.
- Intuitive Surgical's Market Leadership: Intuitive Surgical leads the robotic-assisted surgery market and is leveraging AI to analyze extensive surgical data, enhancing the safety and effectiveness of its da Vinci system; despite increased competition, its data advantages and patent protections are expected to ensure long-term returns.
- AI-Driven Industry Transformation: All three companies are actively exploring AI applications, positioning Eli Lilly, Novo Nordisk, and Intuitive Surgical to capitalize on the rapidly evolving healthcare market, driving future growth and innovation.
See More
Eli Lilly and Novo Nordisk Leverage AI to Revolutionize Drug Discovery
- Drug Discovery Efficiency: Eli Lilly's partnership with Nvidia to build the industry's most powerful supercomputer is expected to shorten the drug discovery phase by 1 to 2 years, potentially saving around $2.8 billion in R&D costs, which will enhance profit margins and allow for increased investment in R&D.
- Market Leadership: Eli Lilly holds a leading position in the weight management drug market, and with products like Zepbound and Foundayo, it is poised to significantly benefit from the rapidly growing market demand over the next few years, further enhancing its investment appeal.
- AI Technology Application: Novo Nordisk's collaboration with OpenAI aims to leverage AI to improve drug discovery and development efficiency, particularly in obesity and diabetes treatments; despite facing challenges with slowing sales growth, its robust pipeline still holds strong market potential.
- Robotic Surgery Market Advantage: Intuitive Surgical leads the robotic-assisted surgery market and is utilizing AI to analyze vast amounts of surgical data to enhance the safety and effectiveness of its da Vinci system; despite increasing competition, its market moat and ongoing revenue growth suggest a positive outlook.
See More
Viking Launches VK3019 Trial, Sparking Buyout Speculation
- Trial Launch: Viking Therapeutics has initiated a Phase 1 trial for VK3019, aimed at assessing safety and tolerability in obese patients, which is expected to bolster the company's competitive edge in the weight-loss drug market.
- Buyout Speculation: The launch of VK3019 has intensified speculation about a potential acquisition by Novo Nordisk, especially as retail traders highlight the possibility of large-scale acquisitions by Novo in the near future.
- Positive Market Reaction: VKTX shares have risen 41% over the past year, and following the trial launch, traders are expressing 'extremely bullish' sentiment, anticipating that strong trial results could trigger a buyout, with potential prices exceeding $200 per share.
- Multiple Formulation Development: Viking is also advancing an oral version of VK2735 and plans to initiate a Phase 3 obesity trial for this formulation later this year, demonstrating the company's diversified strategy in the weight-loss drug sector to meet market demands for safe and sustainable weight-loss therapies.
See More
United Airlines, Corning, and Absci Reach Record Highs Amid Positive Market Trends
- Oil Price Boost for UAL: United Airlines' stock reached a record high of $130.6 as benchmark oil prices fell to their lowest levels since before the Iran conflict, alleviating supply disruption fears and enhancing profit outlook.
- Tech Innovations Drive Growth: The airline launched its first transatlantic flight equipped with SpaceX's Starlink and partnered to offer live TV during flights, reinforcing investor confidence in its long-term strategy.
- Surge in Fiber Network Demand: Corning's stock hit $217.09 as investors focused on the rising demand for optical networking components amid the AI boom, particularly due to a long-term deal with Amazon that is expected to significantly boost product demand.
- Positive Clinical Data for ABS-201: Absci's stock climbed to a four-year high of $11 after promising results for its hair-loss treatment ABS-201 and completing a $100 million public offering, attracting several prominent investors.
See More
Lilly Launches MedicareGLP-1Bridge Program for Obesity Treatments
- New Medicare Pathway: Lilly announced the MedicareGLP-1Bridge program effective July 1, 2026, allowing eligible Medicare Part D patients to access Foundayo and Zepbound for $50 per month, marking a significant increase in treatment options for obesity.
- Expanded Coverage: This program will provide broad GLP-1 drug coverage for Medicare Part D patients for the first time, potentially benefiting around 20 million eligible patients and promoting obesity treatment accessibility, particularly among adults aged 65 and older.
- Significant Clinical Outcomes: Clinical trials demonstrated that Foundayo and Zepbound resulted in meaningful weight loss in patients aged 65 and older, with Foundayo achieving an average weight loss of 13% in non-diabetic patients at the highest dose, while Zepbound showed over 56.7% of patients losing at least 20% of their body weight over 72 weeks, highlighting its effectiveness in older populations.
- Long-term Strategic Implications: This initiative not only enhances the accessibility of Lilly's obesity medications but also solidifies its leadership in chronic disease treatment, reflecting the company's commitment to recognizing obesity as a chronic condition, which is expected to drive future sales growth and market share expansion.
See More
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals
- Acquisition Completed: Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, aimed at expanding its neuroscience portfolio, particularly in sleep medicine.
- Drug Development Progress: Centessa's lead drug candidate, Cleminorexton, is undergoing Phase 2a clinical studies targeting narcolepsy and other sleep disorders, indicating significant market potential and therapeutic prospects.
- Financial Structure: Under the agreement, Lilly acquired Centessa for $38 per share in cash, along with a non-transferable contingent value right of up to $9 per share, potentially adding $1.5 billion in value upon achieving specific regulatory milestones.
- Market Performance: Lilly's stock has traded between $623.78 and $1,182.73 over the past year, currently priced at $1,111.53, reflecting a 0.51% increase from the previous trading day, indicating positive market sentiment regarding the acquisition.
See More
Three Healthcare Stocks Positioned to Thrive with AI
- Eli Lilly's AI Innovation: Eli Lilly's partnership with Nvidia to build the industry's most powerful supercomputer is expected to shorten the drug discovery phase by 1-2 years, potentially saving around $2.8 billion in R&D costs, enhancing profit margins, and lowering drug prices for patients.
- Novo Nordisk's AI Application: Novo Nordisk's collaboration with OpenAI aims to improve drug development efficiency, particularly in obesity and diabetes treatments; despite recent sales growth challenges, its robust pipeline and the promising UBT251 drug could facilitate a future recovery.
- Intuitive Surgical's Market Leadership: Intuitive Surgical leads the robotic-assisted surgery market and is leveraging AI to analyze extensive surgical data, enhancing the safety and effectiveness of its da Vinci system; despite increased competition, its data advantages and patent protections are expected to ensure long-term returns.
- AI-Driven Industry Transformation: All three companies are actively exploring AI applications, positioning Eli Lilly, Novo Nordisk, and Intuitive Surgical to capitalize on the rapidly evolving healthcare market, driving future growth and innovation.
See More
Eli Lilly and Novo Nordisk Leverage AI to Revolutionize Drug Discovery
- Drug Discovery Efficiency: Eli Lilly's partnership with Nvidia to build the industry's most powerful supercomputer is expected to shorten the drug discovery phase by 1 to 2 years, potentially saving around $2.8 billion in R&D costs, which will enhance profit margins and allow for increased investment in R&D.
- Market Leadership: Eli Lilly holds a leading position in the weight management drug market, and with products like Zepbound and Foundayo, it is poised to significantly benefit from the rapidly growing market demand over the next few years, further enhancing its investment appeal.
- AI Technology Application: Novo Nordisk's collaboration with OpenAI aims to leverage AI to improve drug discovery and development efficiency, particularly in obesity and diabetes treatments; despite facing challenges with slowing sales growth, its robust pipeline still holds strong market potential.
- Robotic Surgery Market Advantage: Intuitive Surgical leads the robotic-assisted surgery market and is utilizing AI to analyze vast amounts of surgical data to enhance the safety and effectiveness of its da Vinci system; despite increasing competition, its market moat and ongoing revenue growth suggest a positive outlook.
See More
Viking Launches VK3019 Trial, Sparking Buyout Speculation
- Trial Launch: Viking Therapeutics has initiated a Phase 1 trial for VK3019, aimed at assessing safety and tolerability in obese patients, which is expected to bolster the company's competitive edge in the weight-loss drug market.
- Buyout Speculation: The launch of VK3019 has intensified speculation about a potential acquisition by Novo Nordisk, especially as retail traders highlight the possibility of large-scale acquisitions by Novo in the near future.
- Positive Market Reaction: VKTX shares have risen 41% over the past year, and following the trial launch, traders are expressing 'extremely bullish' sentiment, anticipating that strong trial results could trigger a buyout, with potential prices exceeding $200 per share.
- Multiple Formulation Development: Viking is also advancing an oral version of VK2735 and plans to initiate a Phase 3 obesity trial for this formulation later this year, demonstrating the company's diversified strategy in the weight-loss drug sector to meet market demands for safe and sustainable weight-loss therapies.
See More
United Airlines, Corning, and Absci Reach Record Highs Amid Positive Market Trends
- Oil Price Boost for UAL: United Airlines' stock reached a record high of $130.6 as benchmark oil prices fell to their lowest levels since before the Iran conflict, alleviating supply disruption fears and enhancing profit outlook.
- Tech Innovations Drive Growth: The airline launched its first transatlantic flight equipped with SpaceX's Starlink and partnered to offer live TV during flights, reinforcing investor confidence in its long-term strategy.
- Surge in Fiber Network Demand: Corning's stock hit $217.09 as investors focused on the rising demand for optical networking components amid the AI boom, particularly due to a long-term deal with Amazon that is expected to significantly boost product demand.
- Positive Clinical Data for ABS-201: Absci's stock climbed to a four-year high of $11 after promising results for its hair-loss treatment ABS-201 and completing a $100 million public offering, attracting several prominent investors.
See More
